Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor-Reference-Cited by-同舟云学术

Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor

Published:2014-01 Issue:2 Volume:289 Page:942-955
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Zhang Yingnan,Eigenbrot Charles,Zhou Lijuan,Shia Steven,Li Wei,Quan Clifford,Tom Jeffrey,Moran Paul,Di Lello Paola,Skelton Nicholas J.,Kong-Beltran Monica,Peterson Andrew,Kirchhofer Daniel

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference54 articles.

1. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1). Liver regeneration and neuronal differentiation;Seidah;Proc. Natl. Acad. Sci. U.S.A,2003

2. PCSK9 and LDL cholesterol. Unravelling the target to design the bullet;Costet;Trends Biochem. Sci,2008

3. PCSK9. A convertase that coordinates LDL catabolism;Horton;J. Lipid Res,2009

4. PCSK9 as a therapeutic target of dyslipidemia;Seidah;Expert Opin. Ther. Targets,2009

5. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation;Zhang;J. Biol. Chem,2007

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferritin‐based disruptor nanoparticles: A novel strategy to enhance LDL cholesterol clearance via multivalent inhibition of PCSK9–LDL receptor interaction;Protein Science;2024-08-16

2. Therapeutic implication of targeting mitochondrial drugs designed for efferocytosis dysfunction;Journal of Drug Targeting;2024-08-12

3. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition;European Journal of Clinical Investigation;2024-06-26

4. Potential acridinedione derivatives for the development of a heterobifunctional PROTAC for targeted degradation of PCSK9 protein;Applied Materials Today;2024-06

5. Therapeutic peptides for coronary artery diseases: in silico methods and current perspectives;Amino Acids;2024-05-31